NCT00211393

A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole

A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Manhattan Eye, Ear & Throat Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).

Detailed description

A complete ophthalmic evaluation and tests: autofluorescence and Fluorescein angiography, Color Fundus Photography, OCT, including liver and adrenal functions and pregnancy test, if applicable will be done on the screening visit. If the patient is eligible, the patient will be started on ketoconazole 600 mg per day by mouth for the following next 6 weeks. The patient will be rechecked at weeks 5-6, 10,14 and 18. During all these visits a complete ophthalmic examination autofluorescence, OCT, and color fundus photographs will be done. Repeat Liver and Adrenal function tests will be done at weeks 5-6 and 10 visits. On the exit visit, all the ophthalmic tests and procedures on the baseline visit will be done. Adverse events, and concomitant medications and treatments will be reported on all visits.

Conditions

• Chronic Central Serous Chorioretinopathy

Interventions

Type	Name	Description
DRUG	ketoconazole	600mg. /day for 6 weeks

Timeline

• Start date: 2005-05-01
• Primary completion: 2008-03-01
• Completion: 2008-04-01
• First posted: 2005-09-21
• Last updated: 2012-10-25

Locations

1 site across 1 country: United States